AR045530A1 - PEPTIDES AND COMPOUNDS THAT JOIN THE TROMBOPOYETINE RECEIVER - Google Patents
PEPTIDES AND COMPOUNDS THAT JOIN THE TROMBOPOYETINE RECEIVERInfo
- Publication number
- AR045530A1 AR045530A1 ARP040103101A ARP040103101A AR045530A1 AR 045530 A1 AR045530 A1 AR 045530A1 AR P040103101 A ARP040103101 A AR P040103101A AR P040103101 A ARP040103101 A AR P040103101A AR 045530 A1 AR045530 A1 AR 045530A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- peptides
- compounds
- laarx10
- iegptlrq
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/524—Thrombopoietin, i.e. C-MPL ligand
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Polyethers (AREA)
Abstract
Se describen péptidos y compuestos que se unen a, y activan, al receptor de trombopoyetina (c-mpl o TPO-R) o de algún otro modo actúan como un agonista de TPO. Reivindicación 1: Un compuesto que se une a un receptor de trombopoyetina, en donde dicho compuesto comprende (H-IEGPTLRQ(2-Nal)LAARX10)2K-NH2, donde X10 se selecciona del grupo formado por sarcosina o beta-alanina. Reivindicación 2: El compuesto de acuerdo con la reivindicación 1, en donde dicho compuesto está covalentemente unido a un polímero hidrófilo. Reivindicación 8: Una composición farmacéutica que comprende un compuesto de acuerdo con la reivindicación 1 en combinación con un portador farmacéuticamente aceptable. Reivindicación 23: Un método para tratar a un paciente que sufre de trombocitopenia, que comprende administrar a dicho paciente una dosis terapéuticamente efectiva de un compuesto el cual comprende (H-IEGPTLRQ(2-Nal)LAARX10)2K-NH2, donde X10 se selecciona del grupo formado por sarcosina o beta- alanina. Reivindicación 28: Un método de acuerdo con la reivindicación 27 donde dicho compuesto es administrado antes del transplanta de médula ósea, quimioterapia o terapia de radiación.Peptides and compounds that bind to and activate the thrombopoietin receptor (c-mpl or TPO-R) or otherwise act as a TPO agonist are described. Claim 1: A compound that binds to a thrombopoietin receptor, wherein said compound comprises (H-IEGPTLRQ (2-Nal) LAARX10) 2K-NH2, wherein X10 is selected from the group consisting of sarcosine or beta-alanine. Claim 2: The compound according to claim 1, wherein said compound is covalently bonded to a hydrophilic polymer. Claim 8: A pharmaceutical composition comprising a compound according to claim 1 in combination with a pharmaceutically acceptable carrier. Claim 23: A method of treating a patient suffering from thrombocytopenia, comprising administering to said patient a therapeutically effective dose of a compound which comprises (H-IEGPTLRQ (2-Nal) LAARX10) 2K-NH2, wherein X10 is selected from the group formed by sarcosine or beta-alanine. Claim 28: A method according to claim 27 wherein said compound is administered before bone marrow transplantation, chemotherapy or radiation therapy.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49874003P | 2003-08-28 | 2003-08-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR045530A1 true AR045530A1 (en) | 2005-11-02 |
Family
ID=34272720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040103101A AR045530A1 (en) | 2003-08-28 | 2004-08-27 | PEPTIDES AND COMPOUNDS THAT JOIN THE TROMBOPOYETINE RECEIVER |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US7576056B2 (en) |
| EP (1) | EP1675606B1 (en) |
| JP (1) | JP4848277B2 (en) |
| KR (2) | KR101183875B1 (en) |
| CN (2) | CN102241742B (en) |
| AR (1) | AR045530A1 (en) |
| AU (1) | AU2004270656B2 (en) |
| BR (1) | BRPI0414008B8 (en) |
| CA (1) | CA2537421C (en) |
| CY (1) | CY1118965T1 (en) |
| DK (1) | DK1675606T3 (en) |
| EA (1) | EA009286B1 (en) |
| EC (1) | ECSP066396A (en) |
| ES (1) | ES2626107T3 (en) |
| HK (1) | HK1096873A1 (en) |
| HR (1) | HRP20170810T1 (en) |
| HU (1) | HUE032370T2 (en) |
| IL (1) | IL173965A (en) |
| IS (1) | IS8300A (en) |
| LT (1) | LT1675606T (en) |
| ME (1) | ME00313B (en) |
| MX (1) | MXPA06002292A (en) |
| NO (1) | NO344233B1 (en) |
| NZ (1) | NZ545455A (en) |
| PL (1) | PL1675606T3 (en) |
| PT (1) | PT1675606T (en) |
| RS (2) | RS20060141A (en) |
| SG (1) | SG131110A1 (en) |
| SI (1) | SI1675606T1 (en) |
| TW (1) | TWI348375B (en) |
| UA (1) | UA82710C2 (en) |
| WO (1) | WO2005023834A2 (en) |
| ZA (1) | ZA200602495B (en) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7091311B2 (en) | 1996-06-07 | 2006-08-15 | Smithkline Beecham Corporation | Peptides and compounds that bind to a receptor |
| PT2319928E (en) | 1998-10-23 | 2013-06-28 | Kirin Amgen Inc | Dimeric thrombopoietin peptide mimetics binding to mp1 receptor and having thrombopoietic activity |
| PT1542714E (en) | 2002-09-18 | 2014-06-23 | Janssen Pharmaceuticals Inc | Methods of increasing platelet and hematopoietic stem cell production |
| US20040149235A1 (en) * | 2002-10-04 | 2004-08-05 | Pogue Albert S. | Apparatus and method for removal of waste from animal production facilities |
| WO2005023834A2 (en) | 2003-08-28 | 2005-03-17 | Ortho-Mcneil Pharmaceutical, Inc. | Peptides and compounds that bind to thrombopoietin receptors |
| US7723295B2 (en) * | 2003-08-28 | 2010-05-25 | Ortho-Mcneil Pharmaceutical, Inc. | Peptides and compounds that bind to a receptor |
| US7615533B2 (en) | 2004-08-16 | 2009-11-10 | Janssen Pharmaceutica N.V. | TPO peptide compounds for treatment of anemia |
| EP1986677A2 (en) * | 2006-01-25 | 2008-11-05 | Amgen Inc. | Thrombopoietic compounds |
| TWI458488B (en) * | 2006-02-14 | 2014-11-01 | Janssen Pharmaceutica Nv | Use of tpo peptide compounds and pharmaceutical compositions in the treatment of anemia |
| JP2009526841A (en) * | 2006-02-14 | 2009-07-23 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Use of TPO peptide compounds and pharmaceutical compositions in the treatment of anemia |
| US7981425B2 (en) | 2006-06-19 | 2011-07-19 | Amgen Inc. | Thrombopoietic compounds |
| AU2009256465B2 (en) * | 2008-06-03 | 2015-05-14 | Janssen Pharmaceutica Nv | TPO mimetic peptide for preventing hematological disorder associated with cancer treatment |
| US9295734B2 (en) | 2011-06-23 | 2016-03-29 | Shimadzu Corporation | Branched amphipathic block polymer and molecular aggregate and drug delivery system using same |
| KR20200059213A (en) * | 2017-07-26 | 2020-05-28 | 잔센파마슈티카엔.브이. | Methods to protect vascular integrity induced by targeted radiation therapy |
| MA54830A (en) | 2019-01-25 | 2021-12-01 | Janssen Pharmaceutica Nv | METHODS FOR MITIGATING TOXIC EFFECTS OF VESICANTS AND CAUSTIC GASES |
| CN113660943A (en) | 2019-01-25 | 2021-11-16 | 詹森药业有限公司 | Methods for enhancing protection against organ and vascular injury, hematopoietic recovery and survival in response to systemic radiation/chemical exposure |
| WO2020154585A1 (en) | 2019-01-25 | 2020-07-30 | Janssen Pharmaceutica Nv | Methods for mitigating liver injury and promoting liver hypertrophy, regeneration and cell engraftment in conjunction with radiation and/or radiomimetic treatments |
| IL311797A (en) | 2021-10-01 | 2024-05-01 | Albert Einstein College Of Medicine | Methods of increasing progenitor cell production |
| WO2024095178A1 (en) | 2022-11-01 | 2024-05-10 | Janssen Pharmaceutica Nv | Thrombopoietin mimetic for use in the treatment of acute liver failure |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5326558A (en) | 1989-08-08 | 1994-07-05 | Genetics Institute, Inc. | Megakaryocytopoietic factor |
| IL96477A0 (en) | 1989-12-01 | 1991-08-16 | Amgen Inc | Megakaryocyte production |
| DK167813B1 (en) | 1989-12-07 | 1993-12-20 | Carlbiotech Ltd As | PENTAPEPTIDE DERIVATIVES, PHARMACEUTICAL ACCEPTABLE SALTS, PROCEDURES FOR PREPARING IT AND PHARMACEUTICAL PREPARATIONS CONTAINING SUCH DERIVATIVE |
| US5571508A (en) | 1989-12-18 | 1996-11-05 | Amrad Corporation Limited | Method for the treatment of thrombocytopenia and pharmaceutical compositions useful therefor |
| IT1241395B (en) | 1990-04-02 | 1994-01-10 | Eniricerche Spa | IMMUNOGENIC COMPOUNDS, THE PROCEDURE FOR THEIR SYNTHESIS AND THEIR USE FOR THE PREPARATION OF ANIMALARY VACCINES |
| US5141851A (en) | 1990-04-18 | 1992-08-25 | Board Of Regents, The University Of Texas System | Isolated farnesyl protein transferase enzyme |
| US5250732A (en) | 1991-07-18 | 1993-10-05 | Genentech, Inc. | Ketamine analogues for treatment of thrombocytopenia |
| US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
| DK0644771T4 (en) | 1992-06-11 | 2006-12-27 | Alkermes Inc | Drug system for the delivery of erythropoietin |
| US5358934A (en) | 1992-12-11 | 1994-10-25 | The United States Of America As Represented By The Secretary Of Agriculture | Materials and methods for control of pests |
| AU8124694A (en) | 1993-10-29 | 1995-05-22 | Affymax Technologies N.V. | In vitro peptide and antibody display libraries |
| GB2285446B (en) | 1994-01-03 | 1999-07-28 | Genentech Inc | Thrombopoietin |
| BR9408534A (en) | 1994-02-14 | 1997-08-05 | Zymogenetics Inc | Isolated protein polynucleotide molecule and isolated dna expression vector cultured cell mammal non-human pharmaceutical composition antibody probe and processes to produce a hematopoietic protein to stimulate platelet production in a mammal and cell proliferation to detect in a mixture of molecules of dna a dna molecule and to purify thrombopoietin |
| AU1843595A (en) | 1994-02-14 | 1995-08-29 | University Of Washington | Methods for stimulating erythropoiesis using thrombopoietin |
| WO1995021919A2 (en) | 1994-02-14 | 1995-08-17 | Kirin Brewery Company, Limited | Protein having tpo activity |
| SG79882A1 (en) | 1994-02-14 | 2001-04-17 | Kirin Brewery | Protein having tpo activity |
| CA2167090C (en) | 1994-03-31 | 2002-05-14 | Timothy D. Bartley | Compositions and methods for stimulating megakaryocyte growth and differentiation |
| US5571686A (en) | 1994-04-14 | 1996-11-05 | Massachusetts Institute Of Technology | Method of using megapoietin for prolonging the survival & viability of platlets |
| US5891912A (en) * | 1994-11-04 | 1999-04-06 | Santen Pharmaceutical Co., Ltd. | 1,3-dialkylurea derivatives having a hydroxyl group |
| US5641655A (en) | 1994-11-30 | 1997-06-24 | Zymogenetics, Inc. | Methods for producing thrombopoietin polypeptides using a mammalian tissue plasminogen activator secretory peptide |
| WO1996017062A1 (en) | 1994-11-30 | 1996-06-06 | Zymogenetics, Inc. | Low molecular weight thrombopoietin |
| ES2276401T3 (en) | 1995-04-26 | 2007-06-16 | Kyowa Hakko Kogyo Co., Ltd. | FUSION PROTEINS G-CSF TPO. |
| US5869451A (en) * | 1995-06-07 | 1999-02-09 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
| US6251864B1 (en) * | 1995-06-07 | 2001-06-26 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
| CZ291749B6 (en) | 1995-06-07 | 2003-05-14 | Glaxo Group Limited | Peptide compound binding to and activating the thrombopoietin receptor and pharmaceutical composition |
| US6060052A (en) | 1995-10-30 | 2000-05-09 | Systemix, Inc. | Methods for use of Mpl ligands with primitive human hematopoietic stem cells |
| US5932546A (en) | 1996-10-04 | 1999-08-03 | Glaxo Wellcome Inc. | Peptides and compounds that bind to the thrombopoietin receptor |
| WO2001021180A1 (en) | 1999-09-24 | 2001-03-29 | Smithkline Beecham Corporation | Thrombopoietin mimetics |
| CA2432708C (en) * | 2000-12-22 | 2011-07-12 | Kinerton Limited | Process for the synthesis of a peptide having a trp residue |
| AU2002307062A1 (en) | 2001-04-02 | 2002-10-15 | Purdue Pharma L.P. | Thrombopoietin (tpo) synthebody for stimulation of platelet production |
| PT1542714E (en) | 2002-09-18 | 2014-06-23 | Janssen Pharmaceuticals Inc | Methods of increasing platelet and hematopoietic stem cell production |
| WO2005023834A2 (en) | 2003-08-28 | 2005-03-17 | Ortho-Mcneil Pharmaceutical, Inc. | Peptides and compounds that bind to thrombopoietin receptors |
-
2004
- 2004-08-13 WO PCT/US2004/026422 patent/WO2005023834A2/en active Application Filing
- 2004-08-13 KR KR1020067003755A patent/KR101183875B1/en not_active IP Right Cessation
- 2004-08-13 NZ NZ545455A patent/NZ545455A/en unknown
- 2004-08-13 PT PT47811534T patent/PT1675606T/en unknown
- 2004-08-13 US US10/918,561 patent/US7576056B2/en active Active
- 2004-08-13 LT LTEP04781153.4T patent/LT1675606T/en unknown
- 2004-08-13 EP EP04781153.4A patent/EP1675606B1/en active Active
- 2004-08-13 SG SG200701488-9A patent/SG131110A1/en unknown
- 2004-08-13 CN CN201110134196.XA patent/CN102241742B/en active Active
- 2004-08-13 JP JP2006524705A patent/JP4848277B2/en active Active
- 2004-08-13 ES ES04781153.4T patent/ES2626107T3/en active Active
- 2004-08-13 CN CN2004800314520A patent/CN1871022B/en active Active
- 2004-08-13 SI SI200432391A patent/SI1675606T1/en unknown
- 2004-08-13 EA EA200600477A patent/EA009286B1/en unknown
- 2004-08-13 UA UAA200602523A patent/UA82710C2/en unknown
- 2004-08-13 KR KR1020127014067A patent/KR20120078742A/en not_active Application Discontinuation
- 2004-08-13 DK DK04781153.4T patent/DK1675606T3/en active
- 2004-08-13 ME MEP-2008-485A patent/ME00313B/en unknown
- 2004-08-13 RS YUP-2006/0141A patent/RS20060141A/en unknown
- 2004-08-13 MX MXPA06002292A patent/MXPA06002292A/en active IP Right Grant
- 2004-08-13 AU AU2004270656A patent/AU2004270656B2/en active Active
- 2004-08-13 PL PL04781153T patent/PL1675606T3/en unknown
- 2004-08-13 BR BRPI0414008A patent/BRPI0414008B8/en active IP Right Grant
- 2004-08-13 CA CA2537421A patent/CA2537421C/en active Active
- 2004-08-13 RS YU20060141A patent/RS56387B1/en unknown
- 2004-08-13 HU HUE04781153A patent/HUE032370T2/en unknown
- 2004-08-27 TW TW093125674A patent/TWI348375B/en active
- 2004-08-27 AR ARP040103101A patent/AR045530A1/en active IP Right Grant
-
2006
- 2006-02-14 IS IS8300A patent/IS8300A/en unknown
- 2006-02-24 EC EC2006006396A patent/ECSP066396A/en unknown
- 2006-02-27 IL IL173965A patent/IL173965A/en active IP Right Grant
- 2006-03-24 NO NO20061346A patent/NO344233B1/en unknown
- 2006-03-27 ZA ZA200602495A patent/ZA200602495B/en unknown
-
2007
- 2007-04-16 HK HK07103946.2A patent/HK1096873A1/en not_active IP Right Cessation
-
2017
- 2017-05-30 HR HRP20170810TT patent/HRP20170810T1/en unknown
- 2017-06-15 CY CY20171100628T patent/CY1118965T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR045530A1 (en) | PEPTIDES AND COMPOUNDS THAT JOIN THE TROMBOPOYETINE RECEIVER | |
| JP7257951B2 (en) | Drug conjugates using self-stable linkers with improved physiochemical properties | |
| TW200744636A (en) | Combined treatment with and composition of 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents | |
| RU2012133522A (en) | NEW USE OF IL-1 BETA COMPOUNDS | |
| JP2021505661A5 (en) | ||
| CY1115289T1 (en) | Methods of Treatment Against Inflammation-Related Illness | |
| RU2013120311A (en) | THERAPEUTIC APPLICATION OF TLR AGONIST AND COMBINED THERAPY | |
| PE20070416A1 (en) | PEPTIDE COMPOUNDS AS AGONISTS OF THE TROMBOPOYETIN RECEPTOR | |
| WO2005117954A3 (en) | Compositions and methods for treatment of neovascular diseases | |
| HK1120427A1 (en) | Anti-glypican-3 antibody | |
| EA200400737A1 (en) | PREPARATION OF AMINO ACIDS AND RIBOFLAVIN APPLICABLE TO REDUCE THE TOXIC EFFECT OF CYTOTOXIC CHEMOTHERAPY | |
| CA2444821A1 (en) | Combination therapy using anti-angiogenic agents and tnfa | |
| CY1114163T1 (en) | METHODS OF USE OF ANGIOPYCIN COMPETITORS WITH CARBON CYCLOTHERIC AGENTS TO REDUCE CARDIOTOXICITY AND / OR IMPROVEMENT | |
| Sun et al. | Bisphosphonates for delivering drugs to bone | |
| EA026870B1 (en) | Combination and pharmaceutical composition for treating tumors | |
| RU2014101207A (en) | NEW INDICATIONS FOR USE IN TREATMENT BY ANTIBODIES AGAINST IL-1-BETA | |
| ES2204640T3 (en) | PHARMACEUTICAL PREPARED WITH PROTEIN CONTENT. | |
| KR102483333B1 (en) | Novel peptides and analogs for use in the treatment of oral mucositis | |
| CA2744339A1 (en) | Method for treating parkinson's disease | |
| PE20160994A1 (en) | FIBROBLAST GROWTH FACTOR RECEPTOR-3 COMPOUNDS (FGFR3) AND TREATMENT METHODS | |
| NZ703919A (en) | Treatment of cancer with elevated dosages of soluble fgfr1 fusion proteins | |
| UA98462C2 (en) | Methods for treating autoimmune diseases using a taci-ig fusion molecule | |
| AU2002221622B2 (en) | Antitumor therapy comprising distamycin derivatives | |
| CN1345336A (en) | Antibody and chemokine constructs and their use for treating autoimmune diseases | |
| BRPI0514187A (en) | compound and preventive drug or therapeutic drug |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |